Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 36.00, indicating a potential upside of 31.4% from the current price of HKD 27.40 [1][4][12]. Core Insights - The company has shown strong growth in both assets and liabilities, but there is a need to monitor the decline in net assets. The first quarter of 2025 saw a year-on-year profit growth of 19%, outperforming peers, primarily driven by investment income [2][7]. - Premium income increased by 28% year-on-year, mainly from individual insurance and bancassurance channels, contributing 11.9 and 16.5 percentage points to the growth, respectively [7]. - New business value grew by 67.9% year-on-year in the first quarter, with individual and bancassurance new business premiums increasing by 133% and 95%, respectively [7]. - Total investment income rose significantly by 44% year-on-year, with an annualized total investment return of 5.7%, up by 1.1 percentage points [7]. - The solvency ratio improved significantly, with the core solvency adequacy ratio at 184%, an increase of 60 percentage points from the beginning of the year [7]. Financial Data Summary - Revenue (in million RMB) is projected to be 71,547 in 2023, increasing to 132,555 in 2024, and then slightly decreasing to 131,771 in 2025E [3][14]. - Net profit (in million RMB) is expected to be 8,712 in 2023, rising to 26,229 in 2024, and then decreasing to 23,506 in 2025E [3][14]. - Earnings per share (in RMB) are projected to be 2.79 in 2023, increasing to 8.41 in 2024, and then decreasing to 7.53 in 2025E [3][14]. - The price-to-earnings ratio is projected to be 9.2 in 2023, dropping to 3.1 in 2024, and then slightly increasing to 3.4 in 2025E [3][14]. - The company's total assets are expected to grow from 1,403,257 million RMB in 2023 to 1,921,549 million RMB in 2025E [14][15].
新华保险（01336）：资产、负债两端增长强劲，需关注净资产下降，维持买入